Garmin vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Olathe KS GPS and wearables (NASDAQ: GRMN) $6.3B FY2024 revenue (+18%); auto OEM +69% BMW ramp, fitness +27%, FAA-certified aviation avionics competing with Apple Watch and Honeywell.
About
Garmin Ltd. is a Olathe, Kansas-based GPS navigation and wearable technology company — publicly traded on the NASDAQ (NASDAQ: GRMN) as an S&P 500 Consumer Discretionary component, incorporated in Switzerland — designing and manufacturing GPS devices, aviation instruments, marine electronics, automotive navigation, fitness wearables, and outdoor adventure devices through approximately 21,000 employees worldwide. In fiscal year 2024, Garmin reported revenues of $6.3 billion (+18% year-over-year), with its Auto OEM segment growing 69% following the production ramp of BMW vehicle infotainment systems, and Fitness segment growing 27% on continued strength of the Forerunner, Venu, and Lily wearable lines. Garmin's diversified five-segment model (Auto, Aviation, Marine, Outdoor, Fitness) provides recession resilience — when leisure marine spending declines, aviation and fitness growth compensate — with each segment generating both hardware and recurring software/service revenue from Connect IQ app downloads, Garmin Connect subscriptions, and aviation database subscription services. CEO Cliff Pemble leads Garmin's strategy of hardware excellence in GPS-intensive applications where Apple and Samsung cannot effectively compete: Garmin's aviation GPS units (GNS, GTN, G3X avionics) are FAA-certified instruments embedded in hundreds of thousands of light aircraft cockpits, requiring Garmin-specific recertification to replace.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.